Oppenheimer analyst Suraj Kalia raised the firm’s price target on TransMedics (TMDX) to $175 from $150 and keeps an Outperform rating on the shares following quarterly results. The firm notes the company continues to invest in building a clinical moat across heart and lung, with kidney as the next priority. Double-shifting of planes is necessary to hit long-term margin goals, Oppenheimer adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target raised to $149 from $114 at JPMorgan
- TransMedics price target raised to $160 from $140 at Piper Sandler
- TransMedics price target raised to $152 from $148 at Canaccord
- Balancing Strong Execution With Long-Term Catalysts: Why TransMedics Merits a Hold Rating
- Closing Bell Movers: First Solar down 12% on earnings miss